Prof Fred Saad speaks to ecancer about Prostate-Specific Antigen (PSA) response with darolutamide plus Androgen-Deprivation Therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in ARANOTE.

The ARANOTE study reveals a strong link between PSA response and patient outcomes.

It compares doublet therapy with darolutamide to a single agent, showing better radiographic progression-free survival and PSA response rates.

Patients with undetectable PSA levels below 0.2 have significantly improved outcomes.

While both high and low-volume patients benefit, low-volume patients achieve undetectable PSA more frequently.

The study highlights PSA as a valuable prognostic marker for personalised patient care.